This pilot trial studies the impact of genetic information on developing liver damage caused by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia. Testing saliva samples may help doctors find certain genetic markers that may predict whether participants will tolerate asparaginase, which is given as part of clinical care for acute lymphoblastic leukemia.

NCT03568266

Conditions

1. Acute Lymphoblastic Leukemia

Interventions

1. Procedure: Biospecimen Collection

MeSH:Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid

HPO:Leukemia Lymphoid leukemia

Hepatotoxicity per Common Terminology Criteria for Adverse Events version 4.0 (CTCAE) and defined as > or = grade 3 of both aspartate aminotransferase (AST) and alanine aminotransferase (ALT), or > or = grade 3 bilirubin elevation.. Inclusion Criteria: - Newly diagnosed with acute lymphoblastic leukemia (ALL) - no prior treatment for ALL - Receiving asparaginase as part of the primary treatment regimen - Ability to understand and the willingness to sign a written informed consent - For retrospective recruitment, those who have received asparaginase between 2012 and 2017; and are current patients of University of Southern California (USC) Exclusion Criteria: - Patients who are unable to give informed consent Inclusion Criteria: - Newly diagnosed with acute lymphoblastic leukemia (ALL) - no prior treatment for ALL - Receiving asparaginase as part of the primary treatment regimen - Ability to understand and the willingness to sign a written informed consent - For retrospective recruitment, those who have received asparaginase between 2012 and 2017; and are current patients of University of Southern California (USC) Exclusion Criteria: - Patients who are unable to give informed consent Acute Lymphoblastic Leukemia Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid PRIMARY OBJECTIVES: I. To establish the association between the SOD2 rs4880 genotypes and asparaginase-induced hepatotoxicity in Hispanic patients.

OUTLINE: Participants' SOD2 rs4880 SNP genotype (based on saliva from buccal swabs) will be classified.